Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Ovarian Cancer Treatment Drugs Market

Ovarian Cancer Treatment Drugs Market Trends

Report ID: GMI7703
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Ovarian Cancer Treatment Drugs Market Trends

Rising diagnoses coupled with increased disease awareness, and support initiatives by several organizations is anticipated to aid in market growth. Organizations such as The International Gynecologic Cancer Society (IGCS) and the World Ovarian Cancer Coalition (WOCC) conduct awareness campaigns, disseminating information on risk factors, symptoms, screening, and prevention.
Similarly, ongoing research & development activities by pharmaceutical companies aiming to develop oncology drugs including ovarian cancer drugs is expected to positively impact the market growth. For instance, Pfizer is actively advancing Enzalutamide through clinical development, currently in Phase II trials. This drug is targeted for the treatment of androgen receptor positive (AR+) ovarian cancer, epithelial ovarian cancer, and primary peritoneal or fallopian tube cancer.

Thus, growing pipeline drugs along with rising government support for R&D funding for cancer studies, favourable reimbursement policies, collaborative research, and strategic approaches further contribute to the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for ovarian cancer treatment drugs reached USD 3.5 billion in 2023 and is projected to be worth USD 6.1 billion by 2032 driven by the high incidence of ovarian cancer globally.

The targeted therapy drugs segment accounted for 43.7% revenue share of the ovarian cancer treatment drugs industry in 2023 and is projected to record substantial growth through 2032 owing to the benefits identifying and combating cancer cells precisely and minimizing harm to healthy cells.

North America industry for ovarian cancer treatment drugs held a sizable revenue share in 2023 and is projected to record robust growth through 2032 attributed to the growing number of patients with ovarian cancer across the region.

Some of the top ovarian cancer treatment drugs industry players are F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Astrazeneca, Merck KGaA, Oasmia Pharmaceutical AB, Clovis Oncology, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Allarity Therapeutics, among others.